On the 27th, Hisamitsu Pharmaceuticals <4530.T> announced that it has acquired a third-party allotment of shares in the startup company ORPHE (Shibuya, Tokyo).
ORPHE is a company engaged in walking analysis DX (digital transformation) business for medical and Health Care sectors. It develops sensing solutions to digitize foot movements, enabling high-precision quantification of walking analysis by measuring various aspects of walking. With this investment, the company aims to support the growth of ORPHE's business and actively incorporate advanced external knowledge and Technology in the rapidly growing digital field to strengthen the Business foundations for Health Care commodities and services.
The closing price on the 27th was 4,148 yen, down 2 yen from the previous day.
Provided by Wealth Advisor Company.
